Abstract:The two main pathological hallmarks of Parkinson's disease are loss of dopamine neurons in the substantia nigra pars compacta and proteinaceous amyloid fibrils composed mostly of α-synuclein, called Lewy pathology. Levodopa to enhance dopaminergic transmission remains one of the most effective treatment for alleviating the motor symptoms of Parkinson's disease (Olanow, Mov Disord 34:812-815, 2019). In addition, deep brain stimulation (Bronstein et al., Arch Neurol 68:165, 2011) to modulate basal ganglia circuit activity successfully alleviates some motor symptoms. MRI guided focused ultrasound in the subthalamic nucleus is a promising therapeutic strategy as well (Martinez-Fernandez et al., Lancet Neurol 17:54-63, 2018). However, to date, there exists no treatment that stops the progression of this disease. The findings that α-synuclein can be released from neurons and inherited through interconnected neural networks opened the door for discovering novel treatment strategies to prevent the formation and spread of Lewy pathology with the goal of halting PD in its tracks. This hypothesis is based on discoveries that pathologic aggregates of α-synuclein induce the endogenous α-synuclein protein to adopt a similar pathologic conformation, and is thus self-propagating. Phase I clinical trials are currently ongoing to test treatments such as immunotherapy to prevent the neuron to neuron spread of extracellular aggregates. Although tremendous progress has been made in understanding how Lewy pathology forms and spreads throughout the brain, cell intrinsic factors also play a critical role in the formation of pathologic α-synuclein, such as mechanisms that increase endogenous α-synuclein levels, selective expression profiles in distinct neuron subtypes, mutations and altered function of proteins involved in α-synuclein synthesis and degradation, and oxidative stress. Strategies that prevent the formation of pathologic α-synuclein should consider extracellular release and propagation, as well as neuron intrinsic mechanisms.

Distribution of α-Synuclein Aggregation in the Peripheral Tissues

Structure, Distribution, and Genetic Profile of Α-Synuclein and Their Potential Clinical Application in Parkinson's Disease.

Central Nervous System-Derived Exosomal Alpha-Synuclein in Serum May Be a Biomarker in Parkinson’s Disease

α-Synuclein as a Diagnostic Marker and Therapeutic Target for Parkinson Disease

Biomarkers and the Role of α-Synuclein in Parkinson’s Disease

alpha-Synuclein as a Diagnostic Marker and Therapeutic Target for Parkinson Disease

Alpha-Synuclein Aggregation in Parkinson's Disease

Models of α-synuclein aggregation in Parkinson’s disease

Prion-Like Mechanisms in Parkinson’s Disease

Role of microglial activation induced by α-synuclein in pathogenesis of Parkinson's disease

Protein–protein interactions regulating α-synuclein pathology

Physiological and Pathological Functions of Neuronal Hemoglobin: A Key Underappreciated Protein in Parkinson’s Disease

[Alpha-synuclein interacted proteins: the relevance with the pathogenesis of Parkinson's disease].

Emerging role of microglia in inter-cellular transmission of α-synuclein in Parkinson's disease

Exploring α-synuclein Interaction Partners and their Potential Clinical Implications for Parkinson's Disease

Initiation and propagation of α-synuclein aggregation in the nervous system

Alpha-synuclein in skin as a high-quality biomarker for Parkinson's disease

Dysregulation of peripheral monocytes and pro-inflammation of alpha-synuclein in Parkinson's disease

α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson's disease

Lysosomal dysfunction in α-synuclein pathology: molecular mechanisms and therapeutic strategies

Alpha Synuclein Connects the Gut-Brain Axis in Parkinson’s Disease Patients – A View on Clinical Aspects, Cellular Pathology and Analytical Methodology